Case study For many people with COVID-19, the first sign they had the virus was a loss in their sense of smell. A team from the Kolling Institute and Royal North Shore Hospital investigated the correlation between the virus and early symptoms. Study lead Associate Professor Rory Clifton-Bligh said a loss of smell had emerged as a common symptom of COVID-19 infection, but the current data is relying on subjective, self-reported information. “This study will objectively assess loss of smell with people who have tested positive to COVID-19,” Associate Professor Clifton- Bligh said. “We will be using a validated test kit for smell identification. Depending upon our findings, it may then be possible to develop a rapid screening test. “It’s really pleasing to be involved in such an important study, and we hope it will assist early diagnosis of the virus and future treatment options.
“We hope it will potentially help a large number people across Australia.” RNSH Head of Neurogenetics and
Executive Director of the Kolling Institute Professor
Carolyn Sue said the smell test had been
Rory Clifton Bligh
used before to assess patients with other medical conditions and found it easy to do and interpret. “This new application of the smell test is an exciting way to combine our past expertise with new research collaborations to help solve COVID-19 related health problems for our patients and the general community,” she said. The study team recruited patients who tested positive to COVID-19 and were monitored through the Royal North Shore Virtual Hospital or had been admitted to RNSH with mild-moderate COVID-19 illness.
Publication highlights include: › Fuchs TL, Nassour AJ, Glover A, Sywak MS, Sidhu SB, Delbridge LW, Clifton-Bligh RJ, Gild ML, Tsang V, Robinson BG, Clarkson A, Sheen A, Sioson L, Chou A, Gill AJ. A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. Am J Surg Pathol . 2020 Oct;44(10):1419-1428. doi: 10.1097/PAS.0000000000001505. PMID: 32452872; PMCID: PMC7641183 › Gild ML, Bullock M, Luxford C, Field M, Clifton-Bligh RJ. Congenital Hypoparathyroidism Associated With Elevated Circulating Nonfunctional Parathyroid Hormone Due to Novel PTH Mutation. J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa279. doi: 10.1210/clinem/dgaa279. PMID: 32421798 › Glastras SJ, Cohen N, Dover T, Kilov G, MacIsaac RJ, McGill M, Fulcher GR. The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia. J Clin Med. 2020 Apr 11;9(4):1091. doi: 10.3390/jcm9041091. PMID: 32290465; PMCID: PMC7230791 › Scott ES, Januszewski AS, O’Connell R, Fulcher G, Scott R, Kesaniemi A, Wu L, Colagiuri S, Keech A, Jenkins AJ. Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. J Clin Endocrinol Metab. 2020 Oct 1;105(10):dgaa361. doi: 10.1210/clinem/dgaa361. PMID: 32766757 › Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651. PMID: 32846061
WWW.NSLHD.HEALTH.NSW.GOV.AU 29
Made with FlippingBook - professional solution for displaying marketing and sales documents online